Nov 7, 2023
|
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
|
|
Sep 26, 2023
|
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
|
|
Sep 14, 2023
|
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
|
|
Sep 7, 2023
|
Lumos Pharma Announces Participation in Investor Conferences in September
|
|
Aug 22, 2023
|
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
|
|
Aug 9, 2023
|
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
|
|
Jul 26, 2023
|
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
|
|
Jul 12, 2023
|
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
|
|
Jun 28, 2023
|
Lumos Pharma Announces Departure of Chief Medical Officer
|
|
Jun 21, 2023
|
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
|
|